ClinicalTrials.gg
CompletedNCT05111431Updated Nov 7, 2022

A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

A Phase 3 interventional study of Dexmedetomidine Hydrochloride Nasal Spray and Dexmedetomidine hydrochloride nasal spray blank preparation in Preoperative Sedation of Children, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 2 Years to 6 Years. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
2 Years to 6 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in children.

02

Conditions studied

  • Preoperative Sedation of Children
03

In context

Lead sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Male or female
  3. Subjects requiring elective general anesthesia surgery
  4. Conform to the ASA Physical Status Classification
  5. Meet the weight standard

Exclusion criteria

Exclusion Criteria:

  1. Not suitable for nasal spray
  2. Pediatric populations requiring special care or court/social welfare supervision
  3. Subjects who had been under general anesthesia when they were randomized
  4. Subjects with a history of mental illness and a history of cognitive impairment epilepsy
  5. Subjects with cardiovascular disease
  6. Subjects whose is below the lower limit of normal
  7. Subjects with a history or possibility of a difficult airway
  8. Abnormal liver function and/or abnormal renal function
  9. Adrenoceptor agonists or antagonists or analgesics were used before randomization
  10. Participated in clinical trials (received experimental drugs)
  11. History of to drug ingredients or components
  12. Other circumstances that the investigator judged inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine Hydrochloride Nasal Spray

    Drug: Dexmedetomidine Hydrochloride Nasal Spray

  • Placebo comparator
    Dexmedetomidine hydrochloride nasal spray blank preparation

    Drug: Dexmedetomidine hydrochloride nasal spray blank preparation

Interventions

  • In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray. In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray.

  • DrugDexmedetomidine hydrochloride nasal spray blank preparation

    In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation. In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who meet parent-child separation successful

    Time frame: within 45 minutes after the beginning of administration

  2. Proportion of subjects who meet the Ramsay sedation score of 3 at least once within 45 minutes after the beginning of administration

    Time frame: within 45 minutes after the beginning of administration

Secondary outcomes

  1. Proportion of subjects who meet parent-child separation successful within 45 minutes after the beginning of administration

    The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success is defined as a scale of 3 or 4 per item.

    Time frame: Within 45 minutes after the beginning of administration

  2. Time from the beginning of administration to the successful parent-child separation for the first time through study completion,an average of 3 days

    The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success is defined as a scale of 3 or 4 per item.

    Time frame: an average of 3 days

  3. Proportion of subjects whose the Ramsay score is satisfactory at least once within 45 minutes after the beginning of administration

    Sedation level using the Ramsay scale. Ramsay Satisfaction is defined as a scale of ≥ 3.

    Time frame: Within 45 minutes after the beginning of administration

  4. Time from the beginning of administration to the satisfactory Ramsay score for the first time

    Sedation level using the Ramsay scale. Ramsay Satisfaction is defined as a scale of ≥ 3.

    Time frame: from the beginning of administration to the first successful Ramsay score

  5. Proportion of subjects whose the UMSS Scale is satisfactory at least once within 45 minutes after the beginning of administration

    Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction is defined as a scale of ≥ 2 .

    Time frame: within 45 minutes after the beginning of administration

  6. Time from the beginning of administration to the satisfactory UMSS score for the first time through study completion,an average of 3 days

    Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction is defined as a scale of ≥ 2.

    Time frame: an average of 3 days

  7. Time of anesthesia awakening through study completion,an average of 3 days

    Time frame: an average of 3 days

07

Study locations

1 site
  • Beijing Children's Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100045, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in May 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 8, 2021
StartActual
Nov 24, 2021
Primary completionActual
May 20, 2022
CompletionActual
May 20, 2022
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05111431
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Nov 24, 2021
Primary completion
May 20, 2022
Completion
May 20, 2022
Last update
Nov 7, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion